NVX-CoV2373 COVID-19 Vaccine Description
NVX-CoV2373 is a prefusion protein coronavirus vaccine candidate made using Novavax’s proprietary nanoparticle technology, Matrix-M, an adjuvant to enhance immune responses and stimulate high levels of neutralizing antibodies.
Novavax’s patented saponin-based Matrix-M adjuvant has demonstrated a potent and well-tolerated effect by stimulating the entry of antigen-presenting cells into the injection site and enhancing antigen presentation in local lymph nodes, boosting immune response and helping an immunized person make antibodies against the virus.
Novavax identified the recombinant nanoparticle NVX‑CoV2373 vaccine as its lead COVID-19 candidate following pre-clinical testing that demonstrated high immunogenicity and high levels of neutralizing antibodies.
Health Minister Dr Harsh Vardhan inaugurates India s first pneumococcal conjugate vaccine newsonair.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from newsonair.com Daily Mail and Mail on Sunday newspapers.